Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection - PubMed
3 hours ago
- #bispecific antibodies
- #T-cell therapy
- #cancer immunotherapy
- T-cell bispecific antibodies (TCBs) are engineered to bind both T cells and tumor cells, redirecting T cells to kill cancer.
- They activate T cells via TCR signaling and modulate immune checkpoint pathways to enhance anti-tumor immunity.
- TCBs show high efficacy in hematologic cancers but face challenges like cytokine release syndrome (CRS) and neurotoxicity (ICANS).
- Resistance from the immunosuppressive tumor microenvironment (TME) limits their broader clinical use.
- Strategies to improve TCBs include novel antibody formats, combinations with checkpoint inhibitors, and AI-assisted design.